View all news

    JANSSEN PRESENTS LONG TERM PHASE 3 EFFICACY AND SAFETY DATA OF SIRUKUMAB IN RHEUMATOID ARTHRITIS PATIENTS WHO HAD AN INADEQUATE RESPONSE AND/OR WHO WERE INTOLERANT TO ANTI-TNFs

    06/14/2017
    Download(opens in new window)PDF

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com